Key Insights

Highlights

Success Rate

90% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

7.3%

3 terminated out of 41 trials

Success Rate

90.3%

+3.8% vs benchmark

Late-Stage Pipeline

10%

4 trials in Phase 3/4

Results Transparency

25%

7 of 28 completed with results

Key Signals

7 with results90% success

Data Visualizations

Phase Distribution

29Total
Not Applicable (18)
P 1 (2)
P 2 (5)
P 3 (1)
P 4 (3)

Trial Status

Completed28
Unknown8
Terminated3
Not Yet Recruiting2

Trial Success Rate

90.3%

Benchmark: 86.5%

Based on 28 completed trials

Clinical Trials (41)

Showing 20 of 20 trials
NCT06799156Not Yet Recruiting

Clinical Study to Confirm the Safety and Performance of the Virtuoso Phaco-vitrectomy Device

NCT07495319Not ApplicableCompleted

Influence of Tamponade on Retinal Shift in Eyes Undergoing Vitrectomy for Rhegmatogenous Retinal Detachment: A Comparison of Gas Versus Silicone Oil in a Pakistani Population

NCT07237061Not ApplicableCompleted

Patient-preferred Aromatherapy Versus Placebo For Reducing Preoperative Anxiety In Patients Undergoing Eye Surgery

NCT07097038Not ApplicableNot Yet RecruitingPrimary

Analgesic Effect and Safety of Oliceridine and Oxycodone in Vitrectomy

NCT06915948Completed

Postoperative Same Day Closure of Giant Macular Hole With Silicone Oil

NCT05689333Not ApplicableCompletedPrimary

A Study to Evaluate the Safety and Performance of the Vista Probe for Vitrectomy Surgery

NCT04566237Not ApplicableCompletedPrimary

Objective Measurements of the Opacification of the Lens After Vitrectomy

NCT01023009TerminatedPrimary

Postoperative Evolution After Small Gauge Vitrectomy Without Eye Occlusion

NCT04337944Not ApplicableUnknown

Endoscopic Assisted Anterior Hyaloid Peeling in Boston Type 1 Keratoprosthesis (KPro-HP-Endo)

NCT04501367Phase 4UnknownPrimary

Assessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) for the Treatment of Pain, Inflammation, and Cystoid Macular Edema Following 27 Gauge Vitrectomy With Internal Limiting Membrane Peel for the Treatment of Retinal Edema Associated With Macular Pucker.

NCT05446948Not ApplicableCompleted

Observation of the Efficacy of Different Vitrectomy Systems to Treat Proliferative Diabetic Retinopathy

NCT05710458Not ApplicableCompletedPrimary

Performance Comparison of the 25 Gauge 20,000cpm HYPERVIT Dual Blade vs. 10,000cpm ULTRAVIT Vitrectomy Cutter

NCT04409808Not ApplicableTerminatedPrimary

IRIS Alfa Clinical Trial A Monocentric, Academic Clinical Trial Safety Study of a Prototype of a New Vitrectomy Device.

NCT04076072Not ApplicableCompletedPrimary

Beveled-Tip Versus(vs) Standard-Tip Vitrectomy Probe

NCT04404296Not ApplicableUnknownPrimary

Pars Plana Vitrectomy With 25-gauge 20000 Cpm, Bevel-tip Cutter

NCT04360603Not ApplicableUnknown

The Safety Outcomes of 27 Gauge Vitrectomy for Posterior Segment Disease in High Myopia

NCT04346095Phase 4Unknown

Oral Sedation in Vitreoretinal Surgery

NCT03584139Not ApplicableCompleted

IRIS Hook Assisted Phacoemulsification in Vitrectomized Eyes

NCT04055077Not ApplicableUnknown

Influence of HFNO on Spontaneous Ventilation in Patients of Different ASA Risk During Analgo-sedation for Vitrectomy

NCT00799227Phase 2Completed

Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular Edema

Scroll to load more

Research Network

Activity Timeline